VTI is pleased to announce the appointment of Ms. Jean Franchi to its Board of Directors, and as Chair of the Audit and Risk Committee.
Atlanta, Georgia, USA 19 December 2017: Visioneering Technologies, Inc. (VTI), a US-based medical device company (‘Visioneering’ or ‘The Company’) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, is pleased to announce the appointment of Ms. Jean Franchi to its Board of Directors, and as Chair of the Audit and Risk Committee.
Ms. Franchi is a highly regarded business leader with over 20 years of experience in building and leading senior corporate and divisional financial teams from the research and development stage through product launch and commercial operations. Her experience spans both the public and private pharmaceutical, biotech, and diagnostics sectors. Ms. Franchi is currently the CFO of Merrimack Pharmaceuticals, Inc. (MACK), a NASDAQ listed biotechnology company specializing in oncology.
Visioneering’s CEO, Dr. Stephen Snowdy said Ms. Franchi was a natural choice for the role, “Ms. Franchi brings to VTI immensely valuable skills, a wealth of experience, and great passion for taking both private and public companies from early market to full scale commercialization.
“Additionally, as VTI readies for international expansion, Ms. Franchi’s experience in international operations is a highly valuable asset,” Dr. Snowdy said.
Prior to Merrimack Pharmaceuticals, Ms. Franchi spent 16 years at Genzyme Corporation, a US-based biotechnology company now owned by Sanofi S.A., where she held roles of increasing responsibility and was instrumental in preparing the company for its transition from early market introductions to becoming the industry leader in rare disease drug development and commercialization.
Earlier in her career, Ms. Franchi worked in accounting, finance, and sales operations for two diagnostic companies: bioMérieux, Inc., and API, a former division of American Home Products (now Pfizer).
Ms. Franchi holds a Bachelor of Business Administration from Hofstra University, in New York.
